Skandinaviska Enskilda Banken (SEB)’s Astria Therapeutics ATXS Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-130,000	Closed	-$1.7M	–	208
2025 Q4	$1.7M	Buy	+130,000	New	+$1.55M	0.01%	587

Skandinaviska Enskilda Banken (SEB)'s ATXS Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 130,000 shares — an estimated $1.7M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $1.7M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Skandinaviska Enskilda Banken (SEB) reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 130,000 Astria Therapeutics shares in Q1 2026, an estimated $1.7M.
Skandinaviska Enskilda Banken (SEB) first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Skandinaviska Enskilda Banken (SEB)'s Astria Therapeutics position peaked at $1.7M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.